COMP <GO>
ROIV vs JNJ // FREE CASH FLOW YIELD
Roivant Sciences Ltd. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: ROIV 2
— JNJ 11
▲ FREE CASH FLOW YIELD LEADER: JNJ
LAST: $36.91 (-1.63%) • MKT CAP: $27.10B
fcf-yield
-2.80%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
fcf-yield
2.97%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ROIV VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ROIV | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 67.90% | -26.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -14.00% | 25.50% | -39.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | -2.80% | 2.97% | -5.77 | JNJ | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.70% | -94.70 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.50% | -88.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | -65.00% | 6.00% | -71.00 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.59 | +20.41 | ROIV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 8/9 | -5.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 7.20% | -0.30 | ROIV | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.3 | 60.4 | -6.06 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 1.08 | -0.08 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.0x | 23.0x | +5.00 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $27.10B | $662.49B | -$635.39B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ROIV REV | JNJ REV | ROIV GROSS % | JNJ GROSS % | ROIV FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $8.3M | $94.19B | 44.0% | 67.9% | -$758.6M | $19.70B |
| FY 2024 | $29.1M | $88.82B | 44.0% | 69.1% | -$844.0M | $19.84B |
| FY 2023 | $32.7M | $85.16B | 44.0% | 44.0% | -$766.7M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ROIV // BETA 1.00
JNJ // BETA 1.08